Expert Rev Proteomics. 2008;5(2):249-262. Similar to the potential ALS biomarkers reported in serum and plasma, many of the CSF-based studies utilize small subject numbers within the sample groups ...

Clene will soon meet with the Food and Drug Administration to discuss analyses that could support an application for ...

However, in this study we have also discovered that p-tau 181 and 217 might be potential biomarkers that could be suitable for early diagnosis of ALS or for monitoring disease progression and the ...

while correctly ruling out ALS in over 80% of non-ALS cases. The other biomarkers performed poorly, with accuracy rates ...

Precision Care Medicine students work with clinical faculty at Johns Hopkins Medicine to learn how to use machine learning ...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, ...

The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...

“We are thrilled to be the first company to evaluate multiple digital clinical biomarker endpoints in an ALS therapeutic trial to gauge short-term disease progression across key functional ...

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose ...